Press coverage about Veracyte (NASDAQ:VCYT) has been trending somewhat positive on Sunday, Accern Sentiment reports. The research group rates the sentiment of media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Veracyte earned a coverage optimism score of 0.09 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 46.0532211550881 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

VCYT has been the subject of several research analyst reports. BTIG Research reaffirmed a “buy” rating and set a $13.00 target price on shares of Veracyte in a research note on Thursday, August 31st. Piper Jaffray Companies reissued a “buy” rating on shares of Veracyte in a research note on Tuesday, September 12th. ValuEngine lowered shares of Veracyte from a “hold” rating to a “sell” rating in a research note on Tuesday, September 12th. Zacks Investment Research lowered shares of Veracyte from a “buy” rating to a “hold” rating in a research note on Thursday, October 5th. Finally, Janney Montgomery Scott lowered shares of Veracyte from a “buy” rating to a “neutral” rating in a research note on Tuesday, November 7th. One analyst has rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $11.85.

Shares of Veracyte (NASDAQ:VCYT) opened at $6.51 on Friday. The company has a current ratio of 5.19, a quick ratio of 4.86 and a debt-to-equity ratio of 0.59. Veracyte has a 1-year low of $5.75 and a 1-year high of $9.80. The firm has a market cap of $227.39, a P/E ratio of -8.04 and a beta of 1.76.

Veracyte (NASDAQ:VCYT) last posted its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.21) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.21). Veracyte had a negative net margin of 38.19% and a negative return on equity of 52.99%. The firm had revenue of $17.50 million for the quarter, compared to analyst estimates of $19.54 million. During the same period last year, the firm posted ($0.20) EPS. Veracyte’s quarterly revenue was down 5.9% on a year-over-year basis. sell-side analysts expect that Veracyte will post -0.87 EPS for the current year.

In other Veracyte news, insider Christopher M. Hall sold 20,000 shares of the business’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $9.00, for a total transaction of $180,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Chairman Bonnie H. Anderson sold 6,000 shares of the business’s stock in a transaction dated Monday, September 25th. The stock was sold at an average price of $8.44, for a total transaction of $50,640.00. Following the completion of the sale, the chairman now owns 16,000 shares in the company, valued at $135,040. The disclosure for this sale can be found here. Insiders have sold a total of 48,000 shares of company stock worth $435,740 over the last 90 days. Insiders own 13.40% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Veracyte (VCYT) Receives Coverage Optimism Score of 0.09” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another website, it was copied illegally and republished in violation of United States and international copyright law. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/12/24/veracyte-vcyt-receives-coverage-optimism-score-of-0-09.html.

Veracyte Company Profile

Veracyte, Inc is a genomic diagnostics company. The Company uses genomic technology to resolve diagnostic ambiguity. It targets diseases in which patients undergo invasive diagnostic procedures. Its products combine genomic technology, clinical science and machine learning. The Company commercializes over three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis.

Insider Buying and Selling by Quarter for Veracyte (NASDAQ:VCYT)

Receive News & Stock Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related stocks with our FREE daily email newsletter.